Tag: Stability System

How to Implement Stability Testing for Non-Oral Dosage Forms in Compliance with Regulatory Guidelines Ensuring Compliance in Stability Testing for Non-Oral Dosage Forms Introduction Non-oral dosage forms, such as injectables, inhalers, transdermal patches, and ophthalmic solutions, present unique challenges in stability testing due to their distinct formulations, delivery mechanisms, and storage conditions. Ensuring compliance with…

Read More “How to Implement Stability Testing for Non-Oral Dosage Forms in Compliance with Regulatory Guidelines” »

How to Conduct Stability Testing for Biologics Under Biosimilar Regulatory Guidelines Stability Testing for Biologics: Adhering to Biosimilar Guidelines Introduction Biologics, including biosimilars, are complex molecules that require stringent stability testing to ensure their safety, efficacy, and quality. Stability studies for biosimilars must demonstrate that the product remains comparable to its reference biologic under specified…

Read More “How to Conduct Stability Testing for Biologics Under Biosimilar Regulatory Guidelines” »

How to Address Stability Testing for Breakthrough Therapy Drugs under FDA Guidelines Stability Testing for Breakthrough Therapy Drugs: Navigating FDA Requirements Introduction Breakthrough therapy drugs are designated by the FDA for expedited development and review due to their potential to provide substantial improvement over existing therapies for serious conditions. These drugs require specific stability testing…

Read More “How to Address Stability Testing for Breakthrough Therapy Drugs under FDA Guidelines” »

How to Implement ICH Q1A(R2) for Stability Testing of APIs and Drug Products Applying ICH Q1A(R2) Guidelines for Stability Testing of APIs and Drug Products Introduction Stability testing is a critical component of the drug development process, ensuring that Active Pharmaceutical Ingredients (APIs) and finished drug products maintain their intended quality, safety, and efficacy over…

Read More “How to Implement ICH Q1A(R2) for Stability Testing of APIs and Drug Products” »

How to Conduct Stability Studies for Complex Generic Drug Products as per US FDA Guidelines Conducting Stability Studies for Complex Generic Drugs: A US FDA Compliance Guide Introduction Complex generic drugs, which include formulations such as liposomal drugs, injectables, and transdermal systems, require rigorous stability studies to ensure their safety, efficacy, and quality throughout their…

Read More “How to Conduct Stability Studies for Complex Generic Drug Products as per US FDA Guidelines” »

How to Prepare a Stability Testing Plan in Compliance with Global Regulatory Requirements Creating a Comprehensive Stability Testing Plan: A Global Regulatory Perspective Introduction A well-prepared stability testing plan is essential for ensuring that pharmaceutical products maintain their safety, efficacy, and quality throughout their shelf life. Compliance with global regulatory requirements, such as those set…

Read More “How to Prepare a Stability Testing Plan in Compliance with Global Regulatory Requirements” »

How to Conduct Stability Testing for Ophthalmic Products under Regulatory Guidelines Ensuring Stability of Ophthalmic Products: A Regulatory Guide Introduction Ophthalmic products, including eye drops and ointments, require specific stability testing to ensure their safety, efficacy, and quality throughout their shelf life. These products are particularly sensitive to microbial contamination and environmental factors, making rigorous…

Read More “How to Conduct Stability Testing for Ophthalmic Products under Regulatory Guidelines” »

How to Implement Stability Studies for Oncology Drugs under US FDA and EMA Guidelines Stability Studies for Oncology Drugs: Ensuring Compliance with US FDA and EMA Standards Introduction Oncology drugs, which are often life-saving medications, require rigorous stability studies to ensure their safety, efficacy, and quality throughout their shelf life. The US FDA and EMA…

Read More “How to Implement Stability Studies for Oncology Drugs under US FDA and EMA Guidelines” »